Takhzyro Market Report 2026

Takhzyro Market Overview

• The Takhzyro market growth in the historic period has been driven by increasing diagnosis of hereditary angioedema, availability of targeted kallikrein inhibitors • Market expansion is supported by increasing investments in rare disease therapeutics, rising demand for patient-friendly biologics • Growth Driver: Rising Prevalence Of Hereditary Angioedema (HAE) Driving The Market Growth • Market Trend: Advancements In Pediatric Prophylaxis Treatment For Hereditary Angioedema (HAE) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Takhzyro Market?

Takhzyro (lanadelumab-flyo) is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in individuals aged 2 years and older. It functions as a monoclonal antibody that inhibits plasma kallikrein, reducing bradykinin levels and thereby decreasing the frequency and severity of swelling episodes associated with HAE. The main types of indications for takhzyro are hereditary angioedema (HAE) prophylaxis, hereditary angioedema (HAE) acute attacks treatment, and other indications. Hereditary angioedema (HAE) prophylaxis refers to preventive treatment aimed at reducing the frequency and severity of angioedema attacks in individuals with HAE. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies and it is used by several end users, including pediatric, adult, and geriatric.

What Is The Takhzyro Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease therapeutics, rising demand for patient-friendly biologics, expansion of personalized medicine approaches, growing focus on long-term disease prevention, increasing innovation in monoclonal antibody engineering. Major trends in the forecast period include increasing adoption of long-acting hae prophylactic therapies, rising use of monoclonal antibodies in rare diseases, expansion of self-administered injectable treatments, growing focus on preventive hae management, improved patient adherence through extended dosing.

Global Takhzyro Market Segmentation

1) By Clinical Indication: Hereditary Angioedema (HAE) Prophylaxis, Hereditary Angioedema (HAE) Acute Attacks Treatment, Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Takhzyro Market?

The prevalence of hereditary angioedema (HAE) is expected to propel the growth of the takhzyro market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, severe swelling in various body parts, often affecting the airway, and can be life-threatening. Rising cases of hereditary angioedema (HAE) are attributed to increased awareness, improved genetic testing, and the identification of spontaneous mutations in the C1 inhibitor gene, alongside environmental triggers. Takhzyro (lanadelumab) is used to prevent attacks of hereditary angioedema (HAE) by inhibiting kallikrein, thereby reducing bradykinin levels and the frequency and severity of swelling episodes. For instance, in January 2025, according to PubMed, a US-based freely accessible online database of biomedical literature maintained by a government agency, reported that the pooled prevalence of HAE was 1.22 cases per 100,000 people. HAE type 1 made up most of the cases, with a slight female predominance. Therefore, the prevalence of hereditary angioedema (HAE) is driving the growth of the takhzyro industry. The growing healthcare expenditure is significantly driving the growth of the takhzyro market in the future. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Growing healthcare expenditure is due to an aging population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Rising healthcare expenditure drives demand for effective treatments such as takhzyro, influencing pricing and cost-effectiveness evaluations in the market. For instance, in November 2025, according to OECD, a France-based intergovernmental organization, reported that in 2024, OECD countries are estimated to have allocated around 9.3% of their GDP to health on average. Therefore, the growing healthcare expenditure is driving the growth of the takhzyro industry.

Key Players In The Global Takhzyro Market

Major companies operating in the takhzyro market are Takeda Pharmaceuticals Inc.

Global Takhzyro Market Trends and Insights

Major companies operating in the Takhzyro market are focusing on developing advanced pediatric prophylaxis treatments to prevent attacks of hereditary angioedema (HAE) in both adult and pediatric patients. Prophylaxis treatment refers to preventive measures taken to reduce the risk of disease or attacks, including administering medications before potential disease episodes. For instance, in February 2023, Takeda Pharmaceutical Company, a Japan-based biopharmaceutical company, announced that the U.S. FDA had approved the supplemental biologics license application (sBLA) for the expanded use of TAKHZYRO (lanadelumab-flyo) for prophylaxis to prevent HAE attacks in pediatric patients 2 to <12 years of age. The approval was supported by extrapolation of efficacy data from the HELP Study, a Phase 3 trial involving patients 12 to <18 years of age.

Regional Insights

North America was the largest region in the takhzyro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Takhzyro Market?

The takhzyro market consists of sales of single-dose prefilled syringes, single-dose vials, and ready-to-use solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Takhzyro Market Report 2026?

The takhzyro market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the takhzyro industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.